‘Moments of Truth’: Nursing Home Giant Ensign on ‘One Clinical’ Model Behind Earnings Success, $850M Available for Investment 

Following a strong second quarter, Ensign Group (Nasdaq: ENSG) strengthened its outlook for the year, with executives highlighting Wednesday the high occupancy levels at its facilities backed by strength in key clinical metrics.

“[Our Mission] is to dignify post-acute care in the eyes of the world through moments of truth,” Port said during the company’s conference call to discuss quarterly results. “That mission is much more than a statement on a wall. It is the guiding principle behind nearly every decision that’s made across our organization.”

Port attributed Ensign’s consistent performance to its mission-driven culture, underlining his company’s “One Clinical” care model, which combines nursing, therapy, physicians and other clinicians to improve outcomes. He said nearly 60,000 employees follow this approach.

Advertisement

“We call this model One Clinical. In this model, therapy isn’t an ancillary department; it’s one half of our clinical brain,” Port said. It is a clinical operating model that guides how our affiliated operations deliver care every day, and we believe it is one of the most important differentiators of our organization that has been developed over decades.

At the California-based nursing home giant, this integrated approach has influenced everything from fall prevention and wound care to behavior management, functional recovery, hospital utilization, quality measures, and even leading to the development of specialized clinical programs, he explained.

And the proof of the model’s success lies in the most recent data outcomes from the Centers for Medicare and Medicaid Services (CMS), Port said, adding that Ensign’s same-store facilities achieved quality measure ratings 23% above state averages, survey inspection scores 18% above state and 26% above nationwide averages.

Advertisement

Meanwhile, rehospitalization rates fared 15% better than the national average while long-stay emergency department visits stood 24% below the national average, he said.

Ensign also had zero CMS Special Focus Facilities, with more than 80% of skilled nursing operations earning four- or five-star quality ratings and outperforming national averages across all 15 CMS quality measures, including all five claims-based metrics, Port said.

Ensign raised its 2026 guidance following strong second-quarter results, with adjusted earnings per share (EPS) reaching $1.92, up 20.8%, and revenue increasing to $1.4 billion, up 17.3%.

“The corresponding financial results are a direct reflection of a relentless patient-focused culture,” he said. “Occupancy growth is, therefore, more than a financial metric. It’s one of the clearest external validations that an operation is consistently delivering the outcomes and experience.”

Besides Ensign’s One Clinical approach, the integration of therapy and nursing, investments in technology and clinical tools, its local leadership culture that drives accountability and execution every day, Port said.

For the second quarter, Ensign reported GAAP diluted earnings per share of $1.68, up 16.7% from a year earlier.

Over $850M in dry powder

Chief Financial Officer Suzanne Snapper highlighted another quarter of double-digit growth, noting Ensign’s balance sheet strength despite heavy investment.

During the first half of 2026, the company invested more than $460 million to execute its strategic growth plan.

Ensign also has more than $850 million available liquidity, including cash and unused credit capacity, to support future acquisitions and growth. The company owns 183 properties, including 159 debt-free assets, providing additional financial flexibility, she said.

“[W]e currently have more than $592 million available under our line of credit, which, when combined with the cash on our balance sheet, gives us more than 850 million in dry powder for future investments,” she said, she said adding, that the organization’s assets have gained significant value over time, adding even more liquidity to help with future growth.

She also said the company raised its 2026 guidance to $7.75 to $7.85 in diluted EPS and $5.87 billion to $5.92 billion in revenue, reflecting confidence in occupancy gains, improving skilled mix, labor stability and operational strength. However, she did acknowledge that reimbursement, acquisition integration and broader economic conditions remain potential variables.

In terms of growth opportunities, executives expressed optimism about the Southeast region, citing strong performance in Tennessee, South Carolina and Alabama markets. Ensign is eyeing additional adjacent states as attractive expansion markets.

During the question and answer session with financial analysts, executives also addressed the impact of upcoming CMS quality rating changes due to the Care Compare updates, Ensign’s acquisition integration, reimbursement and labor trends.

On CMS’ revised Five-Star Quality Rating methodology, executives said that they had anticipated the federal agency’s updated quality measure thresholds because CMS had signaled for several years that it would periodically recalibrate standards. And while this methodology change will affect ratings at facilities, executives said preliminary internal analysis suggests that the impact will be significantly less severe than broader industry expectations. Moreover, improvements in other components of the 5-Star system will offset some of the quality measure changes, executives explained, resulting in little expected impact on the company’s overall 5-Star ratings.

In discussing recently acquired facilities, executives said the latest acquisitions, particularly in Texas, represent more traditional turnaround opportunities characterized by low occupancy and limited skilled nursing mix. While these facilities are not expected to be accretive in the near term, executives said they are performing in line with expectations.

And as far as reimbursement goes, executives described the Medicaid environment as currently stable, with active engagement across Ensign’s markets and good visibility into reimbursement levels through 2026, and in some states, into next year as well. While they do not anticipate major Medicaid rate increases, they view the stability as encouraging. Management also highlighted favorable Medicare rate updates, ongoing collaboration with managed care organizations and Medicare Advantage. The deeper relationship with the Department of Veterans Affairs has become an increasingly important referral source, they noted.

On labor, executives said contract labor usage has remained low and stable after declining substantially from pandemic levels. Turnover continues to improve faster than the broader skilled nursing industry, according to comparisons with CMS data, while overtime has also trended lower. Management said these improvements benefit both operating costs and quality of care by reducing staff fatigue.

They also discussed their evolving acquisition integration process, noting that while Ensign continues to develop administrators through its Administrator-in-Training (AIT) program, the company has become increasingly effective at retaining talented leaders already working at acquired facilities. Earlier access to local leadership during due diligence has improved the company’s ability to evaluate and retain high-performing managers, strengthening transitions following acquisitions.

On Wednesday, Ensign shares closed at $181.89, down 0.68%, or $1.25.

Companies featured in this article: